Terms: = Lung cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
2713 results:
1. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
[TBL] [Abstract] [Full Text] [Related]
2. Identifying the Multitarget Pharmacological Mechanism of Action of Genistein on lung cancer by Integrating Network Pharmacology and Molecular Dynamic Simulation.
Das R; Woo J
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731403
[TBL] [Abstract] [Full Text] [Related]
3. Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods.
Wu X; Li W; Luo Z; Chen Y
Medicine (Baltimore); 2024 May; 103(19):e38133. PubMed ID: 38728523
[TBL] [Abstract] [Full Text] [Related]
4. SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/akt signaling pathway.
Ai Y; Wan C; Chen Z; Wang Y; Zhao W; Huang W
J Biosci; 2024; 49():. PubMed ID: 38726826
[TBL] [Abstract] [Full Text] [Related]
5. DNAJC24 acts directly with PCNA and promotes malignant progression of LUAD by activating phosphorylation of akt.
Liu D; Zuo R; Liu W; He Y; Wang Y; Yue P; Gong W; Cui J; Zhu F; Luo Y; Qi L; Guo Y; Chen L; Li G; Liu Z; Chen P; Guo H
FASEB J; 2024 May; 38(9):e23630. PubMed ID: 38713100
[TBL] [Abstract] [Full Text] [Related]
6. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract] [Full Text] [Related]
7. The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: Molecular insights and clinical perspective.
Kahkesh S; Khoshnazar SM; Gholinezhad Y; Esmailzadeh S; Hosseini SA; Alimohammadi M; Mafi A
Pathol Res Pract; 2024 May; 257():155316. PubMed ID: 38692125
[TBL] [Abstract] [Full Text] [Related]
8. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/akt Signaling Pathway.
Wei N; Wu X; Yu Y; Zhou H; Cui K; Zhao X; Zhang X
Front Biosci (Landmark Ed); 2024 Apr; 29(4):140. PubMed ID: 38682195
[TBL] [Abstract] [Full Text] [Related]
9. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
10. Elucidating the mechanism of action of Isobavachalcone induced autophagy and apoptosis in non-small cell lung cancer by network pharmacology and experimental validation methods.
Wang L; Wang Z; Ni Y; Wang X; Zhang T; Hu M; Lian C; Wang X; Zhang J
Gene; 2024 Aug; 918():148474. PubMed ID: 38670393
[TBL] [Abstract] [Full Text] [Related]
11. Targeted inhibition of the PI3K/akt/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer.
Li XQ; Cheng XJ; Wu J; Wu KF; Liu T
Cell Mol Biol Lett; 2024 Apr; 29(1):58. PubMed ID: 38649803
[TBL] [Abstract] [Full Text] [Related]
12. Wighteone, a prenylated flavonoid from licorice, inhibits growth of SW480 colorectal cancer cells by allosteric inhibition of akt.
Chen X; Ma R; Wu W; Gao R; Shu Y; Dong M; Guo M; Tang D; Li D; Ji S
J Ethnopharmacol; 2024 Aug; 330():118195. PubMed ID: 38641080
[TBL] [Abstract] [Full Text] [Related]
13. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the akt pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract] [Full Text] [Related]
15. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-akt-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract] [Full Text] [Related]
16. Recent advances in the therapeutic potential of nobiletin against respiratory diseases.
Qin Y; Yang J; Li H; Li J
Phytomedicine; 2024 Jun; 128():155506. PubMed ID: 38522319
[TBL] [Abstract] [Full Text] [Related]
17. Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor.
Zhang X; Lei Y; Chen X; He J; Liu Z; Zhu W; Xu Y; Jin X
Biochem Pharmacol; 2024 May; 223():116155. PubMed ID: 38521474
[TBL] [Abstract] [Full Text] [Related]
18. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/akt signaling and histone H3K36me2 alteration.
Pal S; Kabeer SW; Tikoo K
Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
[TBL] [Abstract] [Full Text] [Related]
19. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
[TBL] [Abstract] [Full Text] [Related]
20. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by akt inhibition.
Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
[TBL] [Abstract] [Full Text] [Related]
[Next]
